3',4'-Methylenedioxy-α-pyrrolidinopropiophenone
| Clinical data | |
|---|---|
| Routes of administration | By mouth, insufflation, vaporization, IV, rectal, sublingual |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Primarily urine (renal) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H17NO3 |
| Molar mass | 247.294 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
3',4'-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP) is a stimulant designer drug. It was sold in Germany in the late 1990s and early 2000s as an ingredient in imitation ecstasy (MDMA) pills. It shares a similar chemical structure with α-PPP and MDPV, and has been shown to have reinforcing effects in rats.